All compounds discussed on this page are sold by BioPharma for in vitro research purposes only. Not intended for human or veterinary use. This content is for informational purposes and does not constitute medical advice.
This SLU-PP-332 research guide covers everything researchers need to know about the first-in-class ERRα/ERRγ agonist that’s reshaping metabolic and exercise physiology research. SLU-PP-332 activates the same gene programs triggered by endurance training — without exercise — making it one of the most unique exercise mimetic compounds available for results-driven studies.
If you’re investigating mitochondrial function, fatty acid oxidation, or exercise-adaptation pathways, SLU-PP-332 offers pharmacological access to mechanisms that no incretin-based peptide can touch.
For the broader metabolic peptide landscape, see our GLP-3 metabolic peptides guide.
What Is SLU-PP-332 and How Does It Work?
SLU-PP-332 is a synthetic agonist of the estrogen-related receptors ERRα and ERRγ — nuclear receptors that serve as master regulators of mitochondrial biogenesis, fatty acid oxidation, and exercise-adaptation gene expression.
Unlike GLP-1 agonists or triple agonists like retatrutide, SLU-PP-332 operates entirely outside the incretin signaling pathway. It doesn’t affect appetite, insulin secretion, or gastric emptying. Instead, it activates the ERR–PGC-1α axis — the same transcriptional program that endurance exercise turns on when muscles contract repeatedly over time.
Mechanism of action:
1. SLU-PP-332 binds ERRα and ERRγ receptors
2. ERR activation recruits PGC-1α coactivator
3. The ERR–PGC-1α complex drives transcription of mitochondrial biogenesis genes
4. Upregulated genes include those controlling fatty acid β-oxidation, oxidative phosphorylation, and mitochondrial DNA replication
5. Net result: enhanced mitochondrial capacity, increased fatty acid oxidation, improved metabolic efficiency in muscle tissue
This is why researchers call SLU-PP-332 an exercise mimetic — it pharmacologically reproduces the metabolic adaptations of endurance training at the molecular level.
ERRα and ERRγ: The Receptors Behind Exercise Adaptation
To understand SLU-PP-332’s research value, you need to understand what ERR receptors actually do.
ERRα (Estrogen-Related Receptor Alpha):
- Constitutively active nuclear receptor expressed in tissues with high oxidative metabolism (skeletal muscle, heart, liver, brown adipose tissue)
- Drives mitochondrial gene expression and fatty acid oxidation programs
- Required for exercise-induced mitochondrial biogenesis
- Knockout models show impaired exercise capacity and reduced oxidative fibers
ERRγ (Estrogen-Related Receptor Gamma):
- Highly expressed in cardiac and skeletal muscle
- Controls the slow-twitch muscle fiber gene program
- Activates vascular endothelial growth factor (VEGF) expression for exercise-adaptive angiogenesis
- Plays a critical role in endurance adaptation
Together, ERRα and ERRγ are the transcriptional switches that convert exercise stimuli into lasting metabolic adaptations. SLU-PP-332 flips those switches pharmacologically — that’s its entire value proposition as a SLU-PP-332 metabolic research tool.
SLU-PP-332 vs. GLP Agonists: Different Pathways, Different Applications
- Target: SLU-PP-332 → ERRα/ERRγ
- Primary Effect: Mitochondrial biogenesis, fatty acid oxidation
- Appetite Effect: None
- Exercise Mimicry: Yes
- Best Research Application: Endurance adaptation, mitochondrial function, metabolic efficiency
- Target: Semaglutide → GLP-1R
- Primary Effect: Insulin secretion, appetite suppression
- Appetite Effect: Strong
- Exercise Mimicry: No
- Best Research Application: Incretin pathway, glycemic control
- Target: Retatrutide → GLP-1R + GIPR + GCGR
- Primary Effect: Appetite suppression + thermogenesis
- Appetite Effect: Strong
- Exercise Mimicry: No (thermogenesis via glucagon, not ERR pathway)
- Best Research Application: Full metabolic pathway activation
SLU-PP-332 doesn’t compete with GLP agonists — it complements them by accessing pathways they can’t reach. For researchers studying complete metabolic models, combining an ERR agonist with a triple agonist compound allows pharmacological control over both energy expenditure and energy intake pathways simultaneously.
Research Data and Applications
Key Research Findings on SLU-PP-332
The peer-reviewed data on SLU-PP-332 demonstrates why it’s become a core tool in ERR agonist research:
Mitochondrial biogenesis:
- SLU-PP-332 significantly increased mitochondrial DNA copy number in muscle tissue
- Upregulated genes controlling oxidative phosphorylation (OXPHOS) complexes I–V
- Enhanced expression of mitochondrial transcription factor A (TFAM)
Fatty acid oxidation:
- Increased complete fatty acid β-oxidation capacity in skeletal muscle
- Upregulated CPT1 (carnitine palmitoyltransferase 1) — the rate-limiting enzyme for mitochondrial fatty acid transport
- Enhanced expression of ACADs (acyl-CoA dehydrogenases) involved in fatty acid breakdown
Endurance capacity in animal models:
- Treated subjects showed significantly improved running endurance without prior exercise training
- Increased proportion of type I (slow-twitch) oxidative muscle fibers
- Elevated PGC-1α and downstream target gene expression
Body composition:
- Reduced fat mass in sedentary animal models
- Preserved lean muscle mass
- Shifted fuel utilization from glucose toward fatty acid oxidation
These findings position SLU-PP-332 as the leading exercise mimetic compound for researchers studying metabolic adaptation outside the incretin pathway.
Practical Research Applications for SLU-PP-332
Exercise Physiology Without Exercise Confounds
One of the biggest challenges in exercise research is isolating molecular mechanisms from the physical stress of exercise itself. SLU-PP-332 solves this by activating exercise-adaptation gene programs without any physical activity. Researchers can study:
- Mitochondrial biogenesis signaling cascades
- Fiber-type switching mechanisms
- Angiogenesis and vascular adaptation
- Metabolic flexibility and fuel selection
Metabolic Dysfunction Models
In obesity and metabolic syndrome models, SLU-PP-332’s ability to increase fatty acid oxidation and mitochondrial capacity makes it valuable for studying:
- Exercise-adjacent interventions for sedentary models
- Mitochondrial dysfunction in metabolic disease
- Fat oxidation capacity in insulin-resistant tissue
Combination Research with GLP Agonists
Because ERR and incretin pathways are entirely independent, researchers can study SLU-PP-332 alongside GLP-1, GIP, or glucagon agonists to model both appetite suppression and exercise-adaptation effects simultaneously. This combination approach — covering energy intake reduction plus exercise-mimetic energy expenditure — mirrors the most effective real-world metabolic interventions.
For the full metabolic peptide landscape including GLP-3 compounds, visit our metabolic health peptides page.
SLU-PP-332 vs. Other Exercise Mimetics
While SLU-PP-332 is the most researched ERR agonist exercise mimetic, it’s useful to understand how it compares to other compounds in the metabolic adaptation space:
- Compound: SLU-PP-332
- Target: ERRα/ERRγ
- Mechanism: Nuclear receptor agonism → PGC-1α coactivation → mitochondrial gene transcription
- Exercise Mimicry: Full (endurance-adaptation gene program)
- Fat Oxidation: Strong increase
- Endurance Enhancement: Demonstrated in animal models
- Compound: AICAR (AMPK activator)
- Target: AMPK
- Mechanism: AMPK activation → PGC-1α upregulation → mitochondrial biogenesis
- Exercise Mimicry: Partial (energy-sensing pathway only)
- Fat Oxidation: Moderate increase
- Endurance Enhancement: Moderate
- Compound: GW501516 (PPARδ agonist)
- Target: PPARδ
- Mechanism: PPARδ activation → fatty acid oxidation gene transcription
- Exercise Mimicry: Partial (endurance gene subset)
- Fat Oxidation: High
- Endurance Enhancement: Demonstrated but safety concerns in research
SLU-PP-332 distinguishes itself by acting at the transcriptional master regulator level (ERR receptors) rather than upstream signaling (AMPK) or parallel nuclear receptors (PPARδ). This produces a more complete exercise-adaptation gene program than either comparator.
Frequently Asked Questions
What does SLU-PP-332 do in research models?
SLU-PP-332 activates ERRα and ERRγ nuclear receptors, which drives the expression of mitochondrial biogenesis genes, fatty acid oxidation enzymes, and endurance-adaptation programs. In research models, it increases mitochondrial capacity, enhances fat oxidation, improves endurance performance, and reduces fat mass — all without exercise.
Is SLU-PP-332 a GLP peptide?
No. SLU-PP-332 targets estrogen-related receptors (ERRα/ERRγ), not GLP-1, GIP, or glucagon receptors. It operates through completely independent pathways. GLP agonists regulate appetite and insulin; SLU-PP-332 regulates mitochondrial function and exercise adaptation. They are complementary, not overlapping. Learn more about GLP peptides in our GLP-3 metabolic peptides guide.
How does SLU-PP-332 compare to actual exercise in research models?
SLU-PP-332 activates a substantial portion of the same gene programs that endurance exercise triggers — particularly mitochondrial biogenesis, fatty acid oxidation, and slow-twitch fiber gene expression. However, it doesn’t replicate all exercise effects. Exercise also induces mechanical stress signaling, systemic hormonal changes, and cardiovascular adaptations that SLU-PP-332 doesn’t directly address. It’s best described as a partial exercise mimetic at the metabolic gene level.
Can SLU-PP-332 be used alongside GLP agonists in research?
Yes. Because ERR and incretin pathways are completely independent, researchers can study SLU-PP-332 in combination with GLP-1, GIP, or glucagon agonists without pharmacological redundancy. This combination addresses both energy intake (incretin pathway) and energy expenditure/mitochondrial function (ERR pathway). See the retatrutide research guide for triple agonist details.
What is an ERR agonist?
ERR (estrogen-related receptor) agonists are compounds that activate ERRα and/or ERRγ nuclear receptors. These receptors control gene programs for mitochondrial biogenesis, fatty acid oxidation, and endurance adaptation. Despite the name, ERR receptors don’t bind estrogen — they’re orphan nuclear receptors that regulate metabolic and exercise-adaptation genes.
Is SLU-PP-332 approved for human use?
No. SLU-PP-332 is sold by BioPharma for in vitro research purposes only. It is not approved for human or veterinary use. This content is informational and does not constitute medical advice.
Related Research Guides
- GLP-3 Metabolic Peptides Guide — Overview of the full metabolic peptide landscape including triple agonists
- Retatrutide Research Guide — Deep dive into the GLP-1/GIP/glucagon triple agonist
- Metabolic Health Peptides — Broader metabolic research compound catalog
Shop SLU-PP-332 for Metabolic Research
First-in-class ERRα/ERRγ agonist exercise mimetic. Activate mitochondrial biogenesis and fatty acid oxidation pathways in your research models.
All compounds discussed on this page are sold by BioPharma for in vitro research purposes only. Not intended for human or veterinary use. This content is for informational purposes and does not constitute medical advice.